US3646121A - 4-bromo-3-hydroxyhippuric acid and cationic salts thereof - Google Patents

4-bromo-3-hydroxyhippuric acid and cationic salts thereof Download PDF

Info

Publication number
US3646121A
US3646121A US886405A US3646121DA US3646121A US 3646121 A US3646121 A US 3646121A US 886405 A US886405 A US 886405A US 3646121D A US3646121D A US 3646121DA US 3646121 A US3646121 A US 3646121A
Authority
US
United States
Prior art keywords
bromo
acid
hydroxyhippuric acid
water
cationic salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US886405A
Other languages
English (en)
Inventor
Leon Ellenbogen
Robert Gerard Kelly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of US3646121A publication Critical patent/US3646121A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
    • C07C243/38—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C247/00—Compounds containing azido groups

Definitions

  • histamine is implicated in a number of physiological functions including, for example, the nervous system, peripheral circulation, gastric hyperacidity, and allergic manifestations such as hay fever.
  • the decanboxylation of histidine by the specific enzyme histidine decarboxylase results in the formation of histamine in mammals.
  • Our invention is based upon the discovery that 4-bromo-3-hydroxyhippuric acid is a potent inhibitor of the enzyme histidine decarboxylase with resultant inhibition of histamine formation in mammals.
  • the mode of action of the compounds of the present invention thus differs from that of known antihistaminic compounds which ordinarily merely counteract the existing released or formed histamine.
  • non-toxic, pharmaceutically acceptable cationic salts of 4-bromo-3-hydroxyhippuric acid include, for example, the non-toxic metal cations such as the sodium ion, potassium ion, calcium ion, magnesium ion as well as the organic aminecations such as the tri- (lowenalkyDamine cations (e.g., triethylamine), procaine, and the like.
  • the effectiveness of the compounds of the present invention in inhibiting the activity of the enzyme histidine decarboxylase was determined by the method of Levine and Watts, Biochemical Pharmacology 15, 841-849 (1966) with the modifications of Ellenbogen et al., Biochemical Pharmacology 18, March 1969. In this procedure, the inhibition of rat gastric histidine dccarboxylase activity was determined by measuring the radioactive carbondioxide released from carboxyl-labeled histidine. The incubation-tubes used in the procedure are described-on page 275 of the text Isotopes in Experimental Pharmacology, L. J.
  • 4-bromo-3-hydroxyhippuric acid, and the non-toxic pharmaceutically aceptable cationic salts thereof, have thus been found to be highly useful for inhibiting the activity of histidine decarboxylase in mammals when administered in amounts ranging from about 15 mg. to about 200 mg. per kg. of body weight per day.
  • a preferred dosage regimen for optimum results would be from about 15 mg. to about mg. per kg. of body weight per day, and such dosage units are employed that a total of from about 1.0 g. to 7.0 g. of active ingredient for a subject of about 70 kg. body weight are administered in a 24 hour period.
  • the compounds of the present invention may be administered by any convenient route such as orally, intraperitoneally, subcutaneously, intramuscularly or intravenously.
  • compositions having the desired clarity, stability, and adaptability for parenteral use are obtained by dissolving from 0.10% to 10.0% by weight of active compound in a vehicle consisting of a polyhydric aliphatic alcohol or mixtures thereof. Especially satisfactory are glycerin, propylene glycol, and the polyethylene glycols.
  • the polyethylene glycols consist of a mixture of non-volatile, normally liquid, polyethylene glycols which are soluble in both water and organic liquids and which have molecular weights of from about 200 to about 1500.
  • the amount of active compounddissolved in the above vehicle may vary from 0.10% to 10.0% by weight, it is preferred that the amount of active compound employed be from about 3.0% to about 9.0% by weight.
  • various mitxures of the aforementioned nonvolatile polyethylene glycols may be employed, it is preferred to use a mixture having an average molecular weight of from about 200 to about 400.
  • the parenteral solutions may also contain various preservatives which may be used to prevent bacterial and fungal contaminattion.
  • the preservatives which may be used for such purpose are, for example, benzyl alcohol, myn'stylgamma-picolinium chloride, phenyl, mercuric nitrate, benzalkonium chloride, phenethyl alcohol, p-chlorophenyl-a-glycerol ether, methyl and propyl parabens, and thimerosal.
  • antioxidants include, for example, sodium bisulfite, sodium metabisulfite, and sodium formaldehyde sulfoxylate. Generally, from about 0.05% to about 0.2% concentrations of antioxidant are employed.
  • the preferred concentration of active compound is 25 to 50 mg./ml. of the finished compositions when intramuscular injection is the purpose for which the compositions are intended. They are equally adapted to intravenous administration when diluted with water or diluents employed in intravenous therapy such as isotonic glucose in appropriate quantities. For this use, initial concentrations down to about 10 to 25 mg./ml. of active compound are satisfactory. They are also adapted to oral administration when diluted with drinking water.
  • the compounds of the present invention may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard or soft gelatin capsules, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet.
  • the compounds of this invention may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gum, and the like.
  • Such compositions and preparation should contain at least 0.1% of active compound.
  • the percentage in the compositions and preparations may, of course, be varied and may conveniently be between about to about 75% or more of the weight of the unit.
  • the amount of active compound in such therapeutically useful compositions or preparations is such that a suitable dosage will be obtained.
  • Preferred compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains between about and 200 milligrams of active compound.
  • the tablets, troches, pills, capsules and the like may also contain the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; an excipient such as dicalciurn phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin may be added or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring.
  • a binder such as gum tragacanth, acacia, corn starch or gelatin
  • an excipient such as dicalciurn phosphate
  • a disintegrating agent such as corn starch, potato starch, alginic acid and the like
  • a lubricant such as magnesium stearate
  • a sweetening agent such as sucrose, lactose or saccharin may be added or a flavoring agent
  • any material may be present as coatings or to otherwise modify the physical form of the dosage unit, for instance, tablets, pills or capsules may be coated with shellac, sugar, or both.
  • a syrup or elixir may contain the active compounds, sucrose as a sweetening agent, methyl and propyl parabens as preservatives, a dye and a flavoring such as cherry or orange flavor.
  • any material used in preparing any dosage unit form should be pharmaceutically pure and substantially nontoxic in the amounts employed.
  • Example 1 Preparation of 4-bromo-3-hydroxyhippuric acid
  • a 5.0 gram (0.023 mole) portion of 4-bromo3-hydroxybenzoic acid [J.A.C.S. 68, 574 (1946)] is refluxed in 50 ml. of ethanol, containing 1.1 ml, (about 5%) of concentrated sulfuric acid, for three hours.
  • the solution is allowed to cool, 50 ml. of water is added and the mixture is extracted three times with ether.
  • the ether extract is dried over magnesium sulfate for 1.5 hours.
  • the filtered solution is pumped to dryness leaving a white solid which is recrystallized from a 50:50 mixture of ethanol and water.
  • the white crystals are collected by filtration and dried yielding 4.3 grams (75.8%) of ethyl 4-bromo-3-hydroxybenzoate, melting point 83"- 85 C.
  • the 0.92 gram of hydrazide derivative is dissolved in 15 ml. of water containing 0.5 ml. of concentrated hydrochloric acid. The solution is cooled to 0 C. and 5 ml. of an ice cold 10% solution of sodium nitrite is slowly added with stirring. The azide derivative precipitates out, is filtered and washed with cold water.
  • the azide derivative is suspended in a cold solution of 8 ml. of a 7.5% glycine/water solution. Cold 1 N sodium hydroxide is added dropwise so that the temperature remains below 15 C. When all of the azide has dissolved, the pale yellow solution is warmed to room temperature and acidified to pH 2 with concentrated hydrochloric acid. The solution is extracted with three 10 ml. portions of ethyl acetate and the ethyl acetate is dried over sodium sulfate.
  • Example 2 Preparation of sodium 4-bromo-3- hydroxyhippurate
  • 27.4 g. of 4- bromo 3 hydroxyhippuric acid was dissolved 27.4 g. of 4- bromo 3 hydroxyhippuric acid and 5.4 g. of sodium methoxide and the resulting solution was evaporated to dryness. There was thus obtained sodium 4 bromo-3- hydroxyhippurate as a white powder.
  • Example 4 Preparation of tablet formulation
  • the active ingredient, lactose and corn starch (for mix) are blended together.
  • the corn starch (for paste) is suspended in water at a ratio of 10 grams of corn starch per 80 ml. of water and heated with stirring to form a. paste.
  • This paste is then used to granulate the mixed powders.
  • the wet granules are passed through a No. 8 screen and dried at F.
  • the dry granules are passed through a No. 16 screen.
  • the mixture islubricated with magnesium stearate and compressed-into tablets in a suitable tableting machine. Each tablet contains 300 milligrams of active ingredient.
  • Example 5 Preparation of intramuscular formulation Ingredient: Amount, percent 4-bromo-3-hydroxyhippuric acid 2.5 Parabens (4:1 mixture of methyl and propyl) 0.1 Water for injection 100 The parabens are dissolved in about one-half the volume of Water for injection at 80 C. with stirring. The solution is cooled to below 40 C. and the active ingredient is dissolved therein. The cooled solution is adjusted to final volume with water for injection and is then sterilized by sterile filtration through a suitable filter.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US886405A 1969-12-18 1969-12-18 4-bromo-3-hydroxyhippuric acid and cationic salts thereof Expired - Lifetime US3646121A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88640569A 1969-12-18 1969-12-18

Publications (1)

Publication Number Publication Date
US3646121A true US3646121A (en) 1972-02-29

Family

ID=25388995

Family Applications (1)

Application Number Title Priority Date Filing Date
US886405A Expired - Lifetime US3646121A (en) 1969-12-18 1969-12-18 4-bromo-3-hydroxyhippuric acid and cationic salts thereof

Country Status (5)

Country Link
US (1) US3646121A (fr)
BE (1) BE760464A (fr)
DE (1) DE2062611A1 (fr)
FR (1) FR2081374B1 (fr)
NL (1) NL7014988A (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148912A (en) * 1973-02-28 1979-04-10 Science Union Et Cie Pharmaceutical compositions and methods of using the same

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0286703A1 (fr) * 1987-04-14 1988-10-19 Klinge Pharma GmbH Dérivés de l'acide benzoique, leur procédé de fabrication et leur utilisation comme médicaments

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148912A (en) * 1973-02-28 1979-04-10 Science Union Et Cie Pharmaceutical compositions and methods of using the same

Also Published As

Publication number Publication date
NL7014988A (fr) 1971-06-22
BE760464A (fr) 1971-06-17
FR2081374A1 (fr) 1971-12-03
FR2081374B1 (fr) 1974-08-23
DE2062611A1 (de) 1971-06-24

Similar Documents

Publication Publication Date Title
US4309430A (en) Pyrazinyl-1,2,4-oxadiazole-5-ones, for treatment of edema, and processes for preparing same
JPS59196877A (ja) チアゾリジン誘導体
JPS636058B2 (fr)
IE50471B1 (en) Substituted oxocarboxylic acids,processes for their preparations,their use and medicaments containing them
US4883798A (en) Pharmaceutical compositions
US3728455A (en) Novel compositions of matter
US3870792A (en) Certain dihydrophthalizines for treating hemorrhage and thrombosis
US5114919A (en) Adjuncts in cancer chemotherapy
GB2093027A (en) 2-amino-3-(halobenzoyl)-methylphenylacetic acids, esters and salts thereof
JPS58188879A (ja) シプロヘプタジン−３−カルボン酸及び構造的に関連した化合物のエステル
US4198431A (en) Alkyl N-(3-trifluoromethylphenyl)-anthranilate
US3769413A (en) Method of inhibiting gastric acid secretion
EP0006452A1 (fr) Acides phénylpropynylamino benzoiques hypoglycémiques, leurs sels, compositions pharmaceutiques les contenant et leur application
US3863010A (en) Compositions of matter and method of use of phenyl and substituted phenyl tetrazines
US3651236A (en) Method for inhibiting histamine formation
US3840539A (en) Phthalazine derivatives
US3714363A (en) Substituted amino guanidine as anti-diabetic agents
US3558600A (en) Alkyl sulfate salts of 1-(p-chlorobenzhydryl)-4-methylhomopiperazines
US5958981A (en) γ-diketone compounds with inhibitory activity against platelet aggregation
US3855283A (en) Levo 1-amino-3-chloro-2-propanol and acid addition salts thereof
US4666922A (en) Method for modulating the immune response
US3876787A (en) Method for lowering blood pressure in mammals
US3760082A (en) Compositions containing 5-amino-3-ethyl-1-phenyl-4-pyrazolecarboxamides and methods of using the same
US3562391A (en) Method of suppressing inflammation in mammals
US3803314A (en) Pharmaceutical compositions and use of n-alkyl-1,4-dihydropyridines